A Single-center, Double-blind Placebo-controlled Parallel Group Phase II Study of the Efficacy and Safety of Rilonacept in Subjects With Cold Contact Urticaria (CCU)
Phase of Trial: Phase II
Latest Information Update: 23 Jul 2018
Price : $35 *
At a glance
- Drugs Rilonacept (Primary)
- Indications Urticaria
- Focus Therapeutic Use
- Acronyms Cures
- 16 Jul 2018 Status changed from active, no longer recruiting to completed.
- 14 Dec 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Feb 2018.
- 14 Dec 2017 Status changed from recruiting to active, no longer recruiting.